Literature DB >> 9827260

The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance.

J R Rees1, R W Pinner, R A Hajjeh, M E Brandt, A L Reingold.   

Abstract

Population-based active laboratory surveillance for invasive mycotic infections was conducted during 1992 and 1993 in three California counties: Alameda, Contra Costa, and San Francisco (population, 2.94 million). The cumulative incidence of invasive mycotic infections was 178.3 per million per year. Invasive mycoses were most commonly caused by Candida (72.8 per million per year), Cryptococcus (65.5), Coccidioides (15.3), Aspergillus (12.4), and Histoplasma (7.1). The clinical significance of other, less common fungi was determined by detailed chart review. The cumulative incidence was determined for zygomycosis (1.7 per million per year), hyalohyphomycosis (1.2), and phaeohyphomycosis (1.0). The most common underlying conditions were human immunodeficiency virus infection (47.4%), nonhematologic malignancy (14.7%), diabetes mellitus (9.9%), and chronic lung disease (9.3%). This represents the first population-based epidemiological assessment of invasive mycoses in the United States.

Entities:  

Mesh:

Year:  1998        PMID: 9827260

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  101 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.

Authors:  H Provine; S Hadley
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

4.  Emerging opportunistic fungal infections: where are we heading?

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

5.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 6.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 7.  Neuro-Ophthalmological Emergencies.

Authors:  João Lemos; Eric Eggenberger
Journal:  Neurohospitalist       Date:  2015-10

Review 8.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

9.  Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy.

Authors:  Shane M Devlin; Bing Hu; Andrew Ippoliti
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 10.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.